NCT06231966View on ClinicalTrials.gov

Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)

NARecruitingINTERVENTIONAL
Enrollment

2,462

Participants

Timeline

Start Date

April 22, 2024

Primary Completion Date

May 6, 2026

Study Completion Date

May 6, 2029

Conditions
Peripheral Artery DiseasePolyvascular Disease
Interventions
DRUG

Combination therapy of high-intensity dose rosuvastatin and ezetimibe

Combination therapy of rosuvastatin 20 mg and ezetimibe 10 mg

DRUG

Rosuvastatin monotherapy for treat-to-target

Rosuvastatin monotherapy for treat-to-target (LDL cholesterol \<70 mg/dL)

Trial Locations (1)

Unknown

RECRUITING

Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER